Artikel
Vaccination status in a large cohort of COVID patients
Suche in Medline nach
Autoren
-
Marie Mikuteit
- Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Hannover; Studiendekanat, Medizinische Hochschule Hannover, Hannover
-
Jacqueline Niewolik
- Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Hannover
-
Georg Mn Behrens
- Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Hannover; Deutsches Zentrum für Infektionsforschung (DZIF) e. V., Braunschweig
-
Dominik Schröder
- Institut für Allgemeinmedizin - Universitätsmedizin Göttingen, Göttingen
-
Kai Vahldiek
- Ostfalia Hochschule für angewandte Wissenschaften, Wolfenbüttel
-
Alexandra Jablonka
- Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Hannover; Deutsches Zentrum für Infektionsforschung (DZIF) e. V., Braunschweig
-
Sandra Steffens
- Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Hannover; Studiendekanat, Medizinische Hochschule Hannover, Hannover
| Veröffentlicht: | 31. August 2022 |
|---|
Gliederung
Text
Introduction: With the vaccinations, we entered a new phase of the global pandemic of COVID-19. The vaccination against SARS-CoV-2 is highly effective[1]. Nevertheless, a part of the people who were vaccinated get a SARS-CoV-2 infection and some of them also suffer from long-term symptoms. The effectiveness of the vaccine to prevent Long COVID is still discussed.
Methods: This analysis is part of the DEFEAT Corona study. With a mixed-method online approach, we recruited 3,938 people in Germany who were more then 18 years old and were able to consent. The online questionnaire consisted of questions about demographic characteristics, whether one had a COVID-19 disease and/or long-term sequelae and about the vaccination status.
Results: Up until March 2022, 3,938 people concluded the first questionnaire. 48.9% of the participants had COVID-19, of those 41.2% stated that they suffer from long-term symptoms. Mean age was 42.2 (±12.9) years.
63.0% of the participants were female, 23.9% were male, 0.3% were divers with 12.9% not stating a gender. From the participants who had COVID-19, 7.4% were hospitalized and 2.7% were treated in an intensive care unit.
16.6% were fully vaccinated prior to SARS-CoV-2 infection. Interestingly, participants who had a SARS-CoV-2 infection prior to being vaccinated suffered significantly more often from Long COVID compared to those who were fully vaccinated prior to infection (64.8% vs. 45.2%; p<0.0001, chi square).
Conclusion: This study showed that participants who were vaccinated prior to a SARS-CoV-2 infection suffer significantly less from LONG COVID.
Disclosures: All authors declare that there are no conflicts of interest.
References
- 1.
- Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B, Förster R, Behrens GMN. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021 Sep;27(9):1525-9. DOI: 10.1038/s41591-021-01449-9
